Effective engineering of the mitochondrial genome

Information

  • Research Project
  • 9406532
  • ApplicationId
    9406532
  • Core Project Number
    R43GM125462
  • Full Project Number
    1R43GM125462-01
  • Serial Number
    125462
  • FOA Number
    PA-16-302
  • Sub Project Id
  • Project Start Date
    8/1/2017 - 6 years ago
  • Project End Date
    1/31/2018 - 6 years ago
  • Program Officer Name
    ANDERSON, VERNON
  • Budget Start Date
    8/1/2017 - 6 years ago
  • Budget End Date
    1/31/2018 - 6 years ago
  • Fiscal Year
    2017
  • Support Year
    01
  • Suffix
  • Award Notice Date
    8/1/2017 - 6 years ago

Effective engineering of the mitochondrial genome

Abstract This proposal leverages our novel, unprecedented, and unique method for editing the mitochondrial genome. B-MoGen has exclusive license to this technology. This proposal will finally provide the final piece to complete the human genome project from a functional perspective since it has been impossible to make targeted gene knockouts in the mitochondrial genome until now. This is critically important given that the mitochondria play pivotal roles in human biology and disease. Indeed, there are many mitochondrial genetic diseases that have been impossible to model in isogenic pairs of cells. In this proposal, we will generate human cell lines, including a human induced pluripotent stem (iPS) cell line, that carry a mitochondrial genome deletion present in the most common human mitochondrial genetic disease called Kearns-Sayre Syndrome (KSS). We will employ our mitoTALE-nickases to introduce 4.9kb deletions spanning position 8469 to position 13147 in the mitochondrial genomes in these cells. We will employ our mitoTALENs to induce heteroplasmic shift of the mitochondrial genomes to those carrying the deletion. Secondly, we will develop tools to make doxycycline and cumate inducible mitoTALEN vectors for allowing conditional generation of mitochondrial deletions and induction of heteroplasmic shift. Finally, we will generate mitoTALE-nickases to target each of the 13 protein encoding components of the mitochondrial genome and each of the 2 encoded ribosomal RNAs (rRNA) in both mouse and human cells.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R43
  • Administering IC
    GM
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    224564
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    859
  • Ed Inst. Type
  • Funding ICs
    NIGMS:224564\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    B-MOGEN BIOTECHNOLOGIES, INC.
  • Organization Department
  • Organization DUNS
    079960066
  • Organization City
    Minneapolis
  • Organization State
    MN
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    55413
  • Organization District
    UNITED STATES